HeMemics Type C Meeting with FDA Blood Applications Division
Summary
Our core competence is applying HeMeDri™, the HeMemics proprietary desiccation technology platform to solve preservation, storage and shipping problems that involve dehydrating and rehydrating proteins, cells and tissues.The company has demonstrated capabilities to deliver commercial reagents for use in blood banks, hospitals and clinics and for transporting mammalian cells at ambient temperature for use in pharmaceutical or academic research labs.Contact: Bruce Campbell--President bcampbell@hememics.com Rockville, MD, February 15, 2014 --( PR.com )-- HeMemics Biotechnologies, Inc. (http://www.hememics.com), a development and manufacturing company, today announced that it will meet with the FDAs blood applications division on February14, 2014.Our core competence is applying HeMeDri™, the HeMemics proprietary desiccation technology platform to solve preservation, storage and shipping problems that involve dehydrating and rehydrating proteins, cells and tissues.The company has demonstrated capabilities to deliver commercial reagents for use in blood banks, hospitals and clinics and for transporting mammalian cells at ambient temperature for use in pharmaceutical or academic research labs.